Cagrilintide and semaglutide together drive record weight loss in global trial CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Comparing the Big 3, Semaglutide, Tirzepatide and Retatrutide : r Mounjaro Caggrillintide Dosage TikTok